Main Menu

Stemline Therapeutics, Inc.

(NASDAQ GS: STML)

Summary

Attention investors who purchased shares of Stemline Therapeutics, Inc. before May 4, 2020:

Rigrodsky & Long is investigating potential claims against the board of directors of Stemline Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by affiliates of Menarini Group.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating Stemline Therapeutics, Inc. (“Stemline”) (NASDAQ GS: STML) regarding possible breaches of fiduciary duties and other violations of law related to Stemline’s agreement to be acquired by affiliates of Menarini Group. Under the terms of the agreement, shareholders of Stemline will receive $11.50 in cash and one contingent vale right (“CVR”) for each share of Stemline they own.

If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at info@rl-legal.com

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page